In June 2020, BSV formed a strategic alliance with LaVoieHealthScience in order to enhance BSV's capabilities to communicate value. <read more here>                     In May 2020, BSV entered into a strategic alliance with FCF Fox Corporate Finance to support funding activities. <read more here>                    
                           COVID-19 Portal               Home      About      Team      Clients      Publications      Downloads      News      Career      Contact

  Both, breadth and depth of Bioscience Valuation's economic assessments as well as the company's excellent knowledge of healthcare markets are invaluable assets for me in order to reach my goals.

Rick Jackson, Chairman and CEO
Jackson Healthcare


Core Services
  Financial Valuation
  Commercial Assessment &

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

  Market Model
  R&D Risk Model
  Valuation Model

Core Services - Investment Decisions

Investment Decisions shall be driven by thorough analyses that integrate
  • all commercial aspects including a drug's current and future competitive environment as well as pharmacoeconomics (also see > Commercial Assessment),
  • the analysis and mitigation of development risk (also see > R&D Productivity Increase),
  • the identification of a company's cost of capital,
  • the calculation of risk-adjusted net present values ('NPVs'),
  • the assessment how value is expected to increase once set milestones have been reached,
  • 'comparables', i.e. market transactions with a known value.

Bioscience Valuation supports management with comprehensive analyses and clear investment recommendations that can be shared with any stakeholder.

A 'top 25' pharma company wished to improve its project prioritization metrics. Bioscience Valuation implemented its valuation methodology by educating the company's newly formed portfolio management team.

A transparent, value-driven prioritization process was tailored to the organiation involving all functions and management levels, including the CEO.

This website uses cookies to ensure you get the best experience on our website.
Privacy Policy